Innoviva, Inc. Common Stock

Innoviva's 3.13 P/E ratio is shockingly depressed for any company, let alone one in pharmaceuticals where pricing power typically commands premiums. The 35.9 RSI suggests oversold conditions with room for mean reversion, while the 11.68% short interest indicates meaningful conviction among bears—though this setup could flip quickly if momentum shifts. Trading well below its 52-week high with such a compressed valuation, the stock sits in contrarian territory, but the magnitude of this discount warrants scrutiny into underlying fundamentals rather than reflexive betting on a snapback.